Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel-group, Multicenter Phase II Clinical Trial to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Long-acting Octreotide Injection in Patients With Acromegaly.

NCT07814651 is registered in ClinicalTrials.gov with CSPC ZhongQi Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT07814651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07814651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel-group, Multicenter Phase II Clinical Trial to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Long-acting Octreotide Injection in Patients With Acromegaly.
Lead sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
April 16, 2024
Completion date
April 23, 2026
Enrollment
78 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly